Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours

Adams, Susan J.; Baum, R. P.; Hertel, Anja; Pm, Schumm-Dräger; Kh, Usadel; G, Hör

doi:10.1097/00006231-199807000-00005

Cited by 74 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…68 Ga-DOTATATE PET CT was superior to 18 F-FDG in the detection of NET because of its higher sensitivity in low-grade tumor. Although some studies have shown a correlation between 18 F-FDG uptake and histology of NET as determined by Ki67 index, 10,11 others have failed to demonstrate such a relationship. 9 Data from PET somatostatin receptor ligand studies are limited.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga‐DOTATATE (DOTA‐DPhe¹,Tyr³‐octreotate) and ¹⁸F‐FDG

Kayani¹,

Bomanji²,

Groves³

et al. 2008

Cancer

434

349

View full text Add to dashboard Cite

BACKGROUND. The aim was to assess the relevant distribution of the novel PET tracer 68Ga‐DOTATATE in neuroendocrine tumors (NETs) with combined positron emission tomography / computed tomography (PET/CT) and compare its performance with that of 18F‐FDG PET/CT. METHODS. The imaging findings with 68Ga‐DOTATATE and 18F‐FDG on 38 consecutive patients with a diagnosis of primary or recurrent NET were compared and correlated with tumor grade on histology based on ki67 and mitotic index. RESULTS. The sensitivity of 68Ga‐DOTATATE PET/CT was 82% (31 of 38) and that of 18F‐FDG PET/CT was 66% (25 of 38). The sensitivity of combined 68Ga‐DOTATATE and 18F‐FDG PET/CT was 92% (35 of 38). There was greater uptake of 68Ga‐DOTATATE than 18F‐FDG in low‐grade NET (median SUV 29 vs 2.9, P < .001). In high‐grade NET there was higher uptake of 18F‐FDG over 68Ga‐DOTATATE (median SUV 11.7 vs 4.4, P = .03). There was a significant correlation with predominant tumor uptake of 68Ga‐DOTATATE or 18F‐FDG and tumor grade on histology (P < .0001). CONCLUSIONS. 68Ga‐DOTATATE PET/CT is a useful novel imaging modality for NETs and is superior to 18F‐FDG for imaging well‐differentiated NET. Functional imaging with both 68Ga‐DOTATATE and 18F‐FDG has potential for a more comprehensive tumor assessment in intermediate‐ and high‐grade tumors. Cancer 2008. ©2008 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

“…To date, however, only a few small series have correlated FDG and/or somatostatin receptor scintigraphy (SSRS) with tumor grade. [8][9][10][11] Aim The purpose of this study was to compare the performance of 68 Ga-DOTATATE and 18 F-FDG in confirmed NET and correlate uptake with tumor grade on histology.…”

mentioning

confidence: 99%

Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga‐DOTATATE (DOTA‐DPhe¹,Tyr³‐octreotate) and ¹⁸F‐FDG

Kayani¹,

Bomanji²,

Groves³

et al. 2008

Cancer

434

349

View full text Add to dashboard Cite

show abstract

“…Follow-up control imaging within 6 mo was done on 36 patients. Findings were considered positive if they corresponded to specific, previously described aspects of malignant disease from neuroendocrine tumor (19)(20)(21)(22).…”

Section: Image Interpretationmentioning

confidence: 99%

Bone Metastases in Patients with Neuroendocrine Tumor: ⁶⁸Ga-DOTA-Tyr³-Octreotide PET in Comparison to CT and Bone Scintigraphy

Putzer¹,

Gabriel²,

Henninger³

et al. 2009

J Nucl Med

189

View full text Add to dashboard Cite

Somatostatin receptor scintigraphy is an accurate imaging modality for the diagnosis of neuroendocrine tumor. Because detection of distant metastases has a major impact on treatment, early diagnosis of metastatic spread is of great importance. So far, no standard procedure has become established for the early diagnosis of bone metastases from neuroendocrine tumor. We compared the diagnostic value of CT with that of the novel somatostatin analog 68 Ga-1,4,7,10-tetraazacyclododecane-N,N9,N$,N999-tetraacetic acid-D-Phe 1 -Tyr 3 -octreotide ( 68 Ga-DOTATOC) in the detection of such metastases. Methods: Fifty-one patients (22 women and 29 men; age range, 32-87 y) with histologically verified neuroendocrine tumor were included in this study. PET scans were fused with CT scans using a vacuum fixation device. 18 F-NaF or 99m Tc-dicarboxypropane diphosphonate bone scans or clinical follow-up served as the reference standard. Results: Twelve of the 51 patients had no evidence of bone metastases on any of the available imaging modalities, and 37 patients had 68 Ga-DOTATOC PET results true-positive for bone metastases. 68 Ga-DOTATOC PET results were true-negative for 12 patients, false-positive for one, and false-negative for another, resulting in a sensitivity of 97% and a specificity of 92%. 68 Ga-DOTATOC PET detected bone metastases at a significantly higher rate than did CT (P , 0.001). Furthermore, conventional bone scans confirmed the results of somatostatin receptor PET but did not reveal additional tumors in any patients. Conclusion: 68 Ga-DOTATOC PET is a reliable, novel method for the early detection of bone metastases in patients with neuroendocrine tumor. Our results show that CT and conventional bone scintigraphy are less accurate than 68 Ga-DOTATOC PET in the primary staging or restaging of neuroendocrine tumor.

show abstract

“…Regardless to PET model, our findings indicate that MCC sites exhibit increased 18 FDG uptake according to routine qualitative and quantitative interpretation. In an attempt to correlate glucose metabolism with MCC biology, we assessed the Ki-67 index as a marker of cycling cells, bearing in mind that neuroendocrine tumors (NETs) with a rapid growth or aggressive behavior were found to be highly 18 FDG-avid, while slow-growing NETs usually showed no or low FDG uptake (21)(22)(23). In the present series, all MCC specimens expressed a large germinative compartment, thereby confirming the importance of cell proliferation as a key factor in the biologic behavior of MCC (24).…”

Section: ------------------------------------------------------------mentioning

confidence: 99%

Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma

et al. 2006

View full text Add to dashboard Cite

Abstract. Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer with neuroendocrine differentiation. We studied the potential value of 18 FDG PET in the management of MCC. Eleven patients with MCC were examined by 18 FDG PET and PET-CT for staging purpose (n=4) or for detection of recurrence (n=7). Qualitative and quantitative interpretation of PET studies was performed routinely. 18 FDG PET observations were compared to clinical and radiological findings. In 6 patients, PET findings were also compared to histology. In 7 patients, the 18 FDG tumor uptake was compared to the MCC proliferative activity expressed by the Ki-67 index. 18 FDG PET was contributive in 10/11 MCC patients. In 7 patients, 18 FDG PET detected focal lesions or a disseminated stage of the disease including dermal, nodal and visceral metastases. In 3 patients, a normal 18 FDG PET confirmed complete remission of disease. Most MCC patients exhibited highly 18 FDG-avid sites suggestive of increased glucose metabolism. This imaging pattern was related to a high proliferative activity (Ki-67 index >50%). In 1 patient with a weakly proliferative nodal MCC (Ki-67<10%), a false negative result was yielded by metabolic imaging. In 4/11 patients, 18 FDG PET revealed an unsuspected second neoplasm in addition to MCC. It is concluded that whole-body 18 FDG PET may be useful in the management of MCC patients. However, a normal 18 FDG PET aspect cannot rule out MCC with low proliferative activity.

show abstract

Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours

Cited by 74 publications

References 0 publications

Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga‐DOTATATE (DOTA‐DPhe¹,Tyr³‐octreotate) and ¹⁸F‐FDG

Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga‐DOTATATE (DOTA‐DPhe¹,Tyr³‐octreotate) and ¹⁸F‐FDG

Bone Metastases in Patients with Neuroendocrine Tumor: ⁶⁸Ga-DOTA-Tyr³-Octreotide PET in Comparison to CT and Bone Scintigraphy

Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma

Contact Info

Product

Resources

About

Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours

Cited by 74 publications

References 0 publications

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDG

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDG

Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy

Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma

Contact Info

Product

Resources

About

Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga‐DOTATATE (DOTA‐DPhe¹,Tyr³‐octreotate) and ¹⁸F‐FDG

Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga‐DOTATATE (DOTA‐DPhe¹,Tyr³‐octreotate) and ¹⁸F‐FDG

Bone Metastases in Patients with Neuroendocrine Tumor: ⁶⁸Ga-DOTA-Tyr³-Octreotide PET in Comparison to CT and Bone Scintigraphy